1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Demographic and clinical features
Patients with MS (n = 53)Healthy Controls (n = 24)P Value
Female (No.) (%)34 (64.2%)16 (66.7%).830
Mean age (yr)43.64 (SD, 12.58)38.12 (SD, 13.2).642
RRMS (No.) (%)40 (75.5%)NANA
Mean disease duration (yr)9.91 (SD, 10.56)NANA
EDSS (median) (range)2.0 (0–7.0)NANA
ARMSS (mean) (SD)3.99 (SD, 2.32)NANA
Treatment
 No therapy (No.) (%)9 (17%)NANA
 Low-efficacy DMT (No.) (%)10 (19%)NANA
 High-efficacy DMT (No.) (%)34 (64%)NANA
  • Note:—RRMS indicates relapsing-remitting MS; NA, not applicable; DMT, disease-modifying therapy.